Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
  1. Home
  2. News
  3. Press releases

Press releases

03.12.2020

Issuance of a 4th tranche of €1.5 million of notes convertible into new shares

DEINOVE immediately strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe...
19.11.2020

DEINOVE signs an Evaluation and Technology Development License with DSM

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that pioneers the application of biodiversity from the natural environment...
12.11.2020

DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020

Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the protocol of the ongoing Phase...
01.10.2020

2020 Half-year results: Stronger financial position and research programs moving forward despite the international context

Clinical program for the antibiotic candidate DNV3837 continues, with the support of investigators in the United States AGIR program (...
15.07.2020

DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses its lead generation platform to develop innovative anti-...
17.06.2020

Issuance of a 3rd tranche of €1.5 million of notes convertible into new shares

DEINOVE immediately strengthens its cash position by €1.5 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that...
04.05.2020

Alexis RIDEAU appointed Deputy Chief Executive Officer of DEINOVE with the ambition to strengthen the Company's strategy for innovation and partnerships

• Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences...
29.04.2020

2019 Annual results: A year of important milestones in both Antibiotics and Cosmetics activities

Significant achievements in antibiotic programs: Initiation of the Phase II trial testing DNV3837 as first-line treatment for severe C...
23.04.2020

Official launch of Luminity®, DEINOVE's new cosmetic active ingredient for a radiant complexion

Luminity® is a concentrate of neurosporene, an extremely rare carotenoid that contributes to skin vitality and a beautiful complexion...
03.04.2020

Issuance of a 2nd tranch of €1 million of notes convertible into new shares

DEINOVE immediately strengthens its cash position by €1 million DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses...
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »

News

  • Press releases
  • Events
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

         

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home